Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 51 - 100 out of 661

Document Document Title
WO/2010/134830A1
Formule (I) and (II). The present invention relates to the use of a new lupane derivative of general formula (I) or (II), or a pharmaceutically acceptable salt, crystal form, complex, hydrate, or hydrolysable ester thereof, for preventin...  
WO/2010/118023A1
Described herein are methods of making drospirenone. Also described are intermediate compounds that may be used to synthesis drospirenone.  
WO/2010/114305A2
The present invention relates to a PEGylated betulin derivative, and a cosmetic composition containing the same. The PEGylated betulin derivative of the present invention is water-soluble and has an excellent UV blocking effect, a white ...  
WO/2010/058795A1
Provided is an antioxidant which is highly safe, inhibits oxidation of biological components, in particular, lipids and is usable as a drug, a food or a drink, a food additive, an external skin preparation and so on. A compound selected...  
WO/2010/028487A1
The instant application is directed to bidesmosidic betulin and betulinic acid saponin derivatives of formula (I), and use thereof as antitumor agents. In particular, said compounds are effective in treating lung carcinomas, colorectal a...  
WO/2009/146811A1
The present invention relates to C-ring-substituted pregn-4-ene-21,17-carbolactones of the general formula I in which R6,7 is an α- or β-methylene and R9 is a hydrogen atom and R11 is a bromine, chlorine or fluorine atom or R9 and R11 ...  
WO/2009/100532A1
The invention relates to 17ß lupane derivatives of formula (I): wherein R1 and X are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, the inventi...  
WO/2009/083268A2
The invention relates to 17-(1'-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (1) wherein the radicals Z, R4, R6a, R6b, R7, R15, R16a, R16b and R18 have the designations given in claim 1, and to the solv...  
WO/2009/082818A1
The invention relates to 21 -keto triterpene compounds of formula (I): wherein R1, X and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...  
WO/2009/083271A1
The invention relates to 15,16-methylene-17-(1 '-propenyl)-17-3'-oxidoestra-4-en-3-one derivatives with general chemical formula (I), wherein Z, R4, R6a, R6b, R7 and R18 have the designations given in claim 1, and to the solvates, hydrat...  
WO/2009/083267A2
The invention relates to steroid-17, 17-lactol-derivatives with the chemical formula (I) and the tautomer forms thereof with general chemical formula (Ia) wherein R4, R6a, R6b, R7, R15, R16a, R16b, R18, R22and Z have the designations giv...  
WO/2009/083272A2
The invention relates to 15α,16α-methylene-17-hydroxy-19-nor-17-pregna-4-en-3-one-2 1-carboxylic acid γ-lactone derivatives having a gestagen effect. They are of general chemical formula (I) wherein Z is selected from the group compri...  
WO/2009/082819A1
The invention relates to 21-keto triterpene compounds of formula (I): wherein R1, X, and Y are as defined herein, and pharmaceutically acceptable salts and solvates thereof. These compounds exhibit significant anti-HIV activity. Thus, th...  
WO/2009/083266A1
The invention relates to 17-hydroxy-19-nor-21-carboxylic acid-steroid γ-lactone derivatives with the chemical formula (I) wherein R4, R6a, R6b, R7, R15, R16a, R16b, R18 and Z have the designations given in claim 1, and to the solvates, ...  
WO/2009/083270A1
The invention relates to (15, 16)-methylene-steroid-(17, 17)-lactol-derivates with general chemical formula (I) and the tautomer forms thereof with general chemical formula (Ia) wherein R4, R6a, R6b, R7, R18, R22 and Z have the designati...  
WO/2009/083269A1
The invention relates to a 15, 16-methylene-17-hydroxy-19-nor-21 -carboxylic acid-steroid γ-lactone-derivative with general chemical formula (I) wherein R4, R6a, R6b, R7 and Z have the designations given in claim 1, and to the solvates,...  
WO/2009/059765A2
The present invention describes a process for the preparation of drospirenone (I) using androstendione as a starting material. In particular, androstendione protected on carbonyl group in position 3 as an enol-ether is functionalized in ...  
WO/2009/020231A1
Disclosed are: a protein having an activity of oxidizing a dammarane triterpene; a gene encoding the protein; and use of the protein or the gene. Specifically disclosed are: a protein having an activity of oxidizing a dammarane triterpen...  
WO/2009/012955A2
A process for the preparation of Drospirenone (I) according to the scheme (A) wherein the substituent R is defined in the description. The process improves the product yield and purity by reducing the formation of undesired side-products...  
WO/2009/000923A2
The present invention relates to a process for the preparation of 17α-(3-hydroxypropyl)- 17β-hydroxysteroids of the formula (I) starting from 17-ketosteroids of the formula (III) via the intermediates of the formula (V) wherein the rad...  
WO/2008/151745A1
The 17ß-cyano-18a-homo-19-nor-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO...  
WO/2008/151746A2
The 17ß-cyano-19-nor-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, where...  
WO/2008/152112A2
The 17ß-cyano-19-androst-4-ene derivatives of the present invention have gestagenic activity. They have the general chemical formula (1), in which Z is selected from the group comprising O, two hydrogen atoms, NOR and NNHSO2R, wherein R...  
WO/2008/137050A2
The present invention encompasses processes for preparing drospirenone and intermediates thereof.  
WO/2008/123093A1
Disclosed is an agent for prevention or treatment of iron overload, which contains 22β-methoxyolean-12-ene-3β,24(4β)-diol or a pharmacologically acceptable salt thereof.  
WO/2008/115281A2
The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.  
WO/2008/091532A1
The present invention concerns novel pharmaceutically active compounds, pharmaceutical compositions containing the same, methods of making the compounds, polymorphic forms of the compounds, the compounds for use as medicaments, and use o...  
WO2007141383A9
The invention relates to compounds derived from betulin, and to the use thereof in plant pest control, particularly as antifeedants for butterfly larvae, beetles and snails. Further, the invention relates to novel betulin derivatives and...  
WO/2008/057420A2
The present invention concerns novel pharmaceutically active triterpene derivatives, pharmaceutical compositions containing the same, their use as medicaments, and the use of the compounds for the manufacture of specific medicaments. The...  
WO/2008/054250A1
The invention relates to organic chemistry and medicine, in particular to virology. More specifically the invention relates to a novel chemical compound n'-{n-[3-oxo-lupen-28-oyl]-9-aminononanoyl} -3-amino-3-phenylpropeonic acid of formu...  
WO2008000070B1
The present invention relates to novel derivatives of glycyrrhetimc acid of Formula (I),  
WO/2008/000521A1
The invention relates to novel 18-methyl-19-nor-androst-4-en-17,17- spiroether of general formula (I), where Z = O, two H, =NOR or =NNHSO2R, R = H, or straight or branched chain C1-4 or C3-4alkyl, R4 = H, halogen, or CF3 and R6 and/or R7...  
WO/2007/145253A1
The object is to provide a highly safe NF-κB activation inhibitor at a low cost which can be used for the prevention or treatment of a disease associated with the activation of NF-κB such as an inflammation or type-2 diabetes. Specific...  
WO/2007/141390A1
The invention relates to conipouns derived from betulin, and to the use thereof as antiviral agents in applications of pharmaceutical industry, particularly as agents against alphaviruses.  
WO/2007/141392A2
The invention relates to compositions of cosmetic and pharmaceutical industries comprising betulonic acid for humans and animals, and further, to the use of betulonic acid in compositions of cosmetic and pharmaceutical industries. The in...  
WO/2007/141391A1
The invention relates to betulin derivatives, and to the use thereof as agents against protozoa of the genus Leishmania and against leishmaniasis in applications of pharmaceutical industry.  
WO/2007/141389A1
The invention relates to compouns derived from betulin, and to the use thereof as antibacterial agents in pharmaceutical and cosmetic applications.  
WO/2007/112043A2
The present invention comprises small molecule inhibitors of cell proliferative conditions, in particular cancer and conditions associated with cancer. For example, associated malignancies include ovarian cancer, cervical cancer, breast ...  
WO/2007/078848A2
This invention relates to a novel process for making 3-O-(3',3'- dimethylsuccinyl)betulinic acid ("DSB")- This invention also relates to methods of treating HIV and related diseases using pharmaceutical compositions comprising salt forms...  
WO/2007/043305A1
Disclosed is a pharmaceutical or beverage/food which can inhibit the production of an adipocytokine, particularly an adipocytokine that can induce the resistance to insulin, to thereby prevent or ameliorate the occurrence of a morbid con...  
WO/2007/009821A1
This invention relates to processes for the production of 3-oxo-pregnane-21,17-carbolactones of formula (II) as well as 3-oxo-pregn-4-ene-21,17-carbolactones of formula (III) by the metal-free oxidation of 17-(3-hydroxypropyl)-3,17-dihyd...  
WO/2007/002411A1
The invention relates to compounds, pharmaceutical compositions and methods useful for treating viral infection.  
WO2005077968B1
The present invention relates to novel compounds which are 7alpha-substituted 17-alkylene-16 alpha-hydroxy steroidal estrogens (see formula I). This invention specifically relates to estrogen derivatives which contain 7 alpha -substituen...  
WO/2006/124956A1
As described herein, the present invention provides compounds useful for treating or lessening the severity of a neurodegenerative disorder. The present invention also provides methods of treating or lessening the severity of such disord...  
WO/2006/123466A1
Use of compounds having cyclolanostane skeletons, for example, 9,19-cyclolanostan-3-ol and 24-methylene-9,19-cyclolanostan -3-ol in drugs, food or drink for improving pancreatic functions as the active ingredient.  
WO2006003013B1
The invention relates to novel 2-substituted estra-1,3,5(10)-trien-17-ones of formula (I), wherein R2 is an C1-C8 alkyl saturated or unsaturated group, an C1-C5-alkyloxy group, an aralkyl- or alkylaryl rest, an -O-CnFmHo rest, wherein n=...  
WO/2006/082126A1
The invention concerns a triterpene alkaloid of general formula (I). The invention also concerns a method for making same and use thereof as medicine.  
WO/2006/072467A1
The invention relates to novel 18-methyl-19-nor-17-pregn-4-en-21,17-carbolactones of general formula (I), where Z = O, H2, =NOR or =NNHSO2R, where R = H, a straight- or branched-chain 1-4 or 3-4 C alkyl group, R4 = H, halogen, methyl or ...  
WO/2006/061309A1
A process is described for the preparation of drospirenone, a synthetic steroid with progestogenic, antimineralocorticoid and antiandrogenic activity, useful for preparing pharmaceutical compositions with contraceptive action; comprising...  
WO/2006/059167A1
The invention relates to an industrial process for the preparation of 17-hydroxy- 6β,7β;15β,16β-bismethylene-3-oxo-17&agr -pregn-4-ene-21-carboxylic acid &gammad -lactone of formula (I) , and to the key-intermediates for this process.  

Matches 51 - 100 out of 661